CVRx, Inc.
10.72+0.37 (+3.57%)
Oct 28, 4:00:00 PM EDT · NasdaqGS · CVRX · USD
Key Stats
Market Cap
279.50MP/E (TTM)
-Basic EPS (TTM)
-2.13Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
CVRx posted solid revenue growth in Q2 FY2025 ended June 30, 2025, hitting $13.6M, up 15.1% y/y from $11.8M and 20.5% q/q (derived), driven by U.S. sales at $12.2M that make up over 90% of the total. Gross margin held steady at 84.3%, while operating loss narrowed to $14.4M from $14.0M y/y, thanks to tighter R&D spending, though SG&A climbed with expansion efforts. Net loss of $14.7M edged up slightly from $14.0M y/y, mainly from higher interest expense on $50M debt maturing 2027-2028 at prime +2.65%, offset by other income; diluted EPS improved to $(0.57) on 26.1M shares, reconciling cleanly without anti-dilution flags. Cash dipped to $95.0M after $20.7M operating burn, but $10.0M from stock issuance keeps liquidity firm. Revenue hinges on Barostim adoption. Yet competition from bigger players looms large.
8-K
CVRx Q2 revenue up 15%
CVRx reported Q2 2025 revenue of $13.6 million, up 15% year-over-year, driven by U.S. heart failure growth to $12.1 million and active implanting centers expanding 27% to 240 since last June. The company appointed Brent Binkowski as COO effective August 11, 2025, to oversee R&D, operations, regulatory, and quality amid scaling efforts. CMS proposed maintaining Barostim in APC 1580 at ~$45,000 outpatient payment for 2026, bolstering reimbursement. Full-year revenue guidance narrowed to $55.0–$57.0 million. Leadership bolsters operations.
8-K
CVRx annual meeting results
CVRx stockholders elected Kevin Ballinger and Mitch Hill as Class I directors at the June 3, 2025 annual meeting, with Ballinger receiving 15,182,085 for votes and Hill 14,338,976, while 848,042 and 1,691,151 votes were withheld respectively amid 6,965,421 broker non-votes. The appointment of Grant Thornton LLP as independent auditors for the fiscal year ending December 31, 2025, passed overwhelmingly with 22,940,803 for votes against just 52,397 against and 2,348 abstentions. Directors serve until 2028. Governance stays steady.
10-Q
Q1 FY2025 results
CVRx posted solid revenue growth to $12.3M in Q1 FY2025 ended March 31, up 15% y/y from $10.8M, driven by U.S. sales of $11.2M that make up 91% of the total. Gross margin held steady at 83.5%, while operating expenses dropped 24% y/y to $23.7M, mainly from lower stock-based compensation, narrowing the operating loss to $13.4M from $22.2M. Net loss improved to $13.8M or $0.53 per diluted share on 25.9M weighted shares, versus $22.2M or $1.04 on 21.2M shares last year; the gap between operating and net loss stems from $1.5M interest expense. Cash dipped to $102.7M from $105.9M q/q, with $12.8M used in operations offset by $9.6M financing inflows, and $50M long-term debt at prime +2.65% matures in 2027-2028. Expenses are shrinking. Yet competition from bigger players in heart failure devices looms large.
8-K
CVRx Q1 revenue rises 15%
CVRx reported Q1 2025 revenue of $12.3 million, up 15% year-over-year, driven by 14% U.S. heart failure growth to $11.1 million from 353 units implanted across 227 active centers. While gross margin dipped to 84%, net loss narrowed to $13.8 million from $22.2 million, aided by lower SG&A after prior CEO option adjustments. Real-world data showed Barostim slashing hospital visits by 85% for heart failure. Momentum builds, yet revenue missed expectations. Full-year revenue guidance holds at $55-58 million.
BSX
Boston Scientific Corporation
100.97-1.46
CBLL
CeriBell, Inc.
12.83-0.06
CV
CapsoVision, Inc.
4.69-0.17
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.95+0.00
INSP
Inspire Medical Systems, Inc.
77.17-1.03
LIVN
LivaNova PLC
53.86-0.42
STIM
Neuronetics, Inc.
3.10+0.01
STME
Stimcell Energetics, Inc.
0.41+0.01
VMD
Viemed Healthcare, Inc.
6.86-0.09
VTAK
Catheter Precision, Inc.
2.56-0.07